First oral dog vaccine for Europe.

A new vaccine named Versican Plus Bb Oral, launched in late October, is used against Bordetella bronchiseptica which is a main causal agent of CIRDC. CIRDC has many causal agents, however Bordetella is one of the most prevalent pathogens related to the complex. Versican Plus Bb Oral is a new liquid vaccine that will be inserted into the mouth which will deliver a more relaxed mode of delivery compared to injectable or intranasal vaccines. Furthermore, the Versican Plus Bb Oral will deliver 12 months of immunity.

Former BSAVA president Michael Day, who welcomed the new vaccine against CIRDC, stated: “I think it is exciting for European vets now to have another option in the way they deliver non-core Bordetella protection. There will be different situations depending on circumstances in which either an oral, intranasal or injectable route of administration will be more appropriate.”